Clostridium News and Research

RSS

Sandia researchers develop SpinDx medical diagnostic tool

Researchers at Sandia National Laboratories have developed a lab-on-a-disk platform that they believe will be faster, less expensive and more versatile than similar medical diagnostic tools.

14 Jul 2012

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Cubist Pharmaceuticals, Inc. today announced the initiation of its pivotal Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, or CDAD, with enrollment of a patient in the first of two planned identical global trials.

13 Jul 2012

Health Canada approves XIAFLEX for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada.

9 Jul 2012

BioSpecifics commences XIAFLEX Phase II trial in human lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma.

27 Jun 2012

Survey of home healthcare practices related to infection control

A healthy boy was infected with antibiotic-resistant bacterium that was traced to his mother's nurse's bag left in the family's car after his mother's home healthcare visit to a patient with the same infection. Although the boy's infection and the patient's infection were never DNA tested, the coincidence was remarkable.

26 Jun 2012

MountainView Hospital first in Nevada to use Xenex’s room disinfection device

In an ongoing effort to improve patient safety, MountainView Hospital today announced it is the first hospital in Nevada to use Xenex Healthcare Services' innovative germ-zapping room disinfection technology to keep patients even safer from infections.

21 Jun 2012

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Researchers have unveiled a novel strategy for neutralizing unwanted molecules and clearing them from the body.

18 Jun 2012

Scientists image structure of bacterium protein coat

Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.

11 Jun 2012

Hospira releases enhancement to TheraDoc clinical surveillance system

Hospira, the world's leading provider of injectable drugs and infusion technologies, today released an important enhancement to its TheraDoc clinical surveillance system designed to support hospital antimicrobial stewardship efforts, with the goal of helping to improve patient outcomes, reduce antimicrobial resistant infections and reduce costs.

11 Jun 2012

BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

In the United States Clostridium difficile or "C. difficile" is now recognized as one of the most dangerous and fastest growing Healthcare Acquired Infections (HAIs) in existence. Now surpassing even Staphylococcus aureus (MRSA), C. difficile infections tripled between 2000 and 2005.

6 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

UV disinfection may reduce CDI in hospitals and LTCFs

In a recently published article, "Decontamination with Ultraviolet Radiation to Prevent Recurrent Clostridium difficile Infection in 2 Roommates in a Long-Term Care Facility" (Infection Control and Hospital Epidemiology, 05/2012), researchers shared the results of a trial that used Tru-D SmartUVC to prevent coincident recurrent CDI episodes in roommates in a Long-Term Care Facility (LTCF).

2 Jun 2012

C. difficile infection on the rise

A study presented by Mayo Clinic researchers during Digestive Disease Week 2012 provides clear evidence that the number of people contracting the hard-to-control and treat bacterial infection Clostridium difficile (C. difficile or C. diff) is increasing, and that the infection is commonly contracted outside of the hospital.

22 May 2012

Some patients appear to be more predisposed for recurrent infection from C. diff

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

22 May 2012

T cell imbalance may put certain people at increased risk of C. difficile infection

University of Cincinnati (UC) researchers have found that an imbalance in the regulation of certain T cells-the cells in the body that fight off infection or attack the system in certain autoimmune diseases-may put certain people at a higher risk of having recurrent cases of Clostridium difficile, or C. Diff, infection.

22 May 2012

Probiotics may reduce risk of antibiotic-associated diarrhea

Consumption of probiotics (live microorganisms, which may occur naturally in foods such as yogurt, intended to confer a health benefit when consumed) is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA.

9 May 2012

Strong link between HAIs and patient readmission after initial hospital stay

New research finds a strong link between healthcare-associated infections (HAIs) and patient readmission after an initial hospital stay. The findings, published in the June 2012 issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), suggest that reducing such infections could help reduce readmissions, considered to be a major driver of unnecessary healthcare spending and increased patient morbidity and mortality.

5 May 2012

Synthetic stool transplant for C. difficile treatment

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.

2 May 2012

FDA clears Great Basin’s first C. diff molecular diagnostic test

Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.

2 May 2012

Amoxicillin-clavulanate may improve small bowel function in children experiencing motility disturbances

The common antibiotic, amoxicillin-clavulanate, may improve small bowel function in children experiencing motility disturbances, according to a study appearing in the June print edition of the Journal of Pediatric Gastroenterology and Nutrition from Nationwide Children's Hospital.

30 Apr 2012